An ROS-responsive, RGC-targeted nanotherapeutic strategy with a TRPV4 antagonist restores autophagic flux and protects RGCs in a rat model of chronic ocular hypertension
Jiarun Song, Xueqi Zhang, Pengwei Huang, Hui Li, Wenhui Liu, Liyan Wang, Ruiqing Wang, Zhuoran Ye, Jingxin Zhang, Zhiyue Zhang, Hui Guo · 2026
Read An ROS-responsive, RGC-targeted nanotherapeutic strategy with a TRPV4 antagonist restores autophagic flux and protects RGCs in a rat model of chronic ocular hypertension by Jiarun Song, Xueqi Zhang, Pengwei Huang, Hui Li, Wenhui Liu, Liyan Wang, Ruiqing Wang, Zhuoran Ye, Jingxin Zhang, Zhiyue Zhang, Hui Guo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13520542.txt.
Description
Jiarun Song and colleagues engineer in 2026 a nanoparticle treatment that delivers a channel-blocking drug directly to retinal ganglion cells in a rat model of chronic high eye pressure. Glaucoma kills those cells slowly, while pressure lowering alone often fails to stop loss.
Prior work showed that overactive TRPV4 channels disturb calcium balance and jam cellular recycling, pushing cells toward death. Particles use a toxin subunit for selective cell entry, with a shell that opens only where reactive oxygen is high. Treatment restored recycling flow and cut cell injury in the model. Precise, on-demand release may reduce dose and side effects compared with free drug.
Catalog record
| CREATOR | Jiarun Song, Xueqi Zhang, Pengwei Huang, Hui Li, Wenhui Liu, Liyan Wang, Ruiqing Wang, Zhuoran Ye, Jingxin Zhang, Zhiyue Zhang, Hui Guo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85978 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |